Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 24Breast Neoplasms 14Neoplasms 12Myelodysplastic Syndromes 12Prostatic Neoplasms 10Multiple Myeloma 8Lung Neoplasms 7Stomach Neoplasms 6Sarcoma 6Ovarian Neoplasms 5Leukemia, Myelomonocytic, Chronic 5Recurrence 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumor 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Solid Tumor 3Pain 3Mucositis 3Lymphoma, T-Cell, Peripheral 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma, Hepatocellular 3Stomatitis 2Small Cell Lung Carcinoma 2Skin Neoplasms 2

Interventions

toripalimab 2sintilimab 2Surveys and Questionnaires 1Pemetrexed 1Paclitaxel 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Lung Cancer × Injections × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡